BALDWIN PARK, CA / ACCESSWIRE / July 26, 2019 / Since 2015, Premier Pharmacy Services has been part of a pharmacy network, designed by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute SAMSCA ...

Please provide your email address to receive an email when new articles are posted on . Blood urea nitrogen level and urinary sodium excretion correlated with response to Samsca, or tolvaptan, in ...

Otsuka and the FDA are notifying healthcare professionals of significant liver injury associated with the use of Samsca (tolvaptan) tablets. Samsca is a selective vasopressin V 2-receptor antagonist ...

HealthDay News — The FDA is advising health care providers to monitor patients who take the hyponatremia drug tolvaptan (Samsca, Otsuka) for hepatic injury, after reports of significant liver injury ...

Samsca tablets approved for hyponatremia The FDA has approved Samsca (tolvaptan tablets, from Otsuka), a once-daily oral vasopressin V2-receptor antagonist, for the treatment of patients with ...

Camber is introducing tolvaptan tablets, the generic of Otsuka’s Samsca. [Read more: Camber wins HDA's DIANA Award] The medication is used to treat hyponatremia, low levels of sodium in your blood, in ...

Samsca, an oral vasopressin V2-receptor antagonist, will be commercialized in the United States by Otsuka America Pharmaceutical, Inc (OAPI). Once-daily Samsca has been shown to significantly raise ...

Please provide your email address to receive an email when new articles are posted on . Samsca, also known as tolvaptan, was safe when combined with conventional diuretics and presented promising ...

Otsuka Pharmaceutical's Samsca (tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of autosomal dominant polycystic kidney disease ...

Samsca was developed over the past 26 years by the efforts of many researchers in Otsuka’s Tokushima, Japan research facility. It is currently used in 14 countries and territories around the world as ...

Regulators in Europe have given the green light to Novartis’ Afinitor for advanced kidney cancer, Genzyme’s cancer drug Mozobil and Otsuka Pharmaceutical Co’s hyponatraemia therapy Samsca. Regulators ...